Nonetheless, in the context of very aggressive double-hit DLBCL, rearranged for both MYC and BCL2, PDX models have brought out the crucial role for BM macrophages in mediating the clinical effect of alkylating agents, suggesting compartment-specific mechanisms of resistance. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.